Context: Psychophysiological onset insomnia (PI) is defined as sleeplessness exceeding 30 min due to learned, sleep-preventing behaviors and hyperarousal at bedtime. This common condition significantly impacts sufferers' health, occupational performance, and interpersonal relationships. Conventional treatment with hypnotics has many shortcomings. Homeopathic medication may present an alternative treatment for this condition.
Objective: The study intended to determine the effect of a homeopathic complex on PI.
Design: The research team designed a randomized, double-blind, placebo-controlled, 4-wk pilot study, using matched pairs.
Setting: The study took place at the Homeopathy Health Clinic at the University of Johannesburg in Johannesburg, South Africa.
Participants: Forty-six males aged between 18 and 40 y with chronic PI were recruited; 28 completed the study- placebo group (n = 14) and experimental group (n = 14).
Interventions: The homeopathic complex was made in 20% alcohol. The placebo consisted of the unmedicated vehicle only.
Outcome Measures: The study used the Pre-sleep Arousal Scale (PSAS) and the Sleep Diary (SD), which assessed sleep-onset latency.
Results: The experimental group showed a statistically significant improvement in presleep arousal as well as sleep onset latency over the 4 wks of the study. The Wilcoxon signed-rank test revealed that the improvement occurred gradually. Intergroup analysis showed through both the PSAS and the SD that the experimental group had outperformed the placebo group by day 28 of the study.
Conclusion: Findings suggest that daily use of the homeopathic complex does have an effect over a 4-wk period on physiological and cognitive arousal at bedtime as well as on sleep onset latency in PI sufferers. Further research on the use of this complex for PI is warranted before any definitive conclusions can be drawn.
Download full-text PDF |
Source |
---|
Homeopathy
December 2024
Brazilian Academic Consortium for Integrative Health-CABSIN, São Paulo, Brazil.
Introduction And Objective: This study presents and analyzes the content of an online Evidence Gap Map (EGM), "", which graphically represents evidence from systematic reviews (SRs) of human clinical trials in homeopathy that were published from 1991 to 2021. The EGM was built according to the guidelines of the International Initiative for Impact Evaluation (3ie), adapted for complex interventions, to represent visually relevant evidence and research gaps.
Presentation Of Evidence Gap Map Content: The interventions, classified as rows, are characterized in the EGM not only by the homeopathic therapeutic strategy but also by individual medicines and potencies.
Cureus
November 2024
Department of Siddha Medicine, Nandha Siddha Medical College and Hospital, Erode, IND.
Dr. S. Padmavathi Iyer is a distinguished cardiologist recognized for her expertise in cardiovascular medicine.
View Article and Find Full Text PDFJ Ayurveda Integr Med
December 2024
Anti-Cancer Drug Screening Facility (ACDSF), Advanced Centre for Treatment, Research & Education in Cancer (ACTREC), Tata Memorial Centre, Kharghar, Navi Mumbai-410210, India; Kode Lab, Tumor Immunology & Immunotherapy (TII) Group, Advanced Centre for Treatment, Research & Education in Cancer (ACTREC), Tata Memorial Centre, Kharghar, Navi Mumbai-410210, India; Homi Bhabha National Institute (HBNI), Training School Complex, Anushakti Nagar, Mumbai 400094, India. Electronic address:
Background: Xenografts in immunodeficient mice play a pivotal role in testing novel anti-cancer treatments. Xenograft models expedite the drug discovery process, offering a cost-effective alternative to conventional animal models and providing essential data for clinical trials. We have followed the approach described by the Developmental Therapeutics Program of the National Cancer Institute (NCI), USA to investigate the therapeutic responses.
View Article and Find Full Text PDFCytokine
January 2025
JSPS Government Homeopathic Medical College, Hyderabad 500013, India. Electronic address:
CD40-CD40-ligand (CD40L) interaction plays crucial immunoregulatory roles, as CD40 signals through different signaling intermediates to convert the messages from CD40L to effector functions. Being a TNFα receptor family member, CD40 binds TNFα receptor-associated factors, assembles signalosome complexes and decrypts the messages from CD40L through different signaling modules to result in residue-specific effector functions. The evidence for such a residue-specific message encryption first came from the CD40L mutations resulting in X-linked hyper-IgM syndrome, as the extent of effects varied with the residue mutated.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!